SurModics Inc (SRDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SurModics Inc (SRDX) has a cash flow conversion efficiency ratio of 0.013x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.41 Million) by net assets ($111.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SRDX company net worth for the company's overall valuation and market capitalisation.
SurModics Inc - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how SurModics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SurModics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SurModics Inc ranked by their cash flow conversion efficiency. Explore SurModics Inc (SRDX) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alpha Tau Medical Ltd
NASDAQ:DRTS
|
0.000x |
|
Grid Dynamics Holdings Inc
NASDAQ:GDYN
|
0.012x |
|
MCAN Mortgage Corporation
TO:MKP
|
0.164x |
|
Waga Energy SA
PA:WAGA
|
0.065x |
|
Life & Banc Split Corp
TO:LBS
|
-0.003x |
|
MarineMax Inc
NYSE:HZO
|
0.018x |
|
Farglory FTZ Investment Holding Co Ltd
TW:5607
|
0.041x |
|
Guangdong Insight Brand Marketing Group Co Ltd
SHE:300781
|
0.006x |
Annual Cash Flow Conversion Efficiency for SurModics Inc (1998–2024)
The table below shows the annual cash flow conversion efficiency of SurModics Inc from 1998 to 2024. View latest SurModics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $118.90 Million | $248.00K | 0.002x | -97.62% |
| 2023-09-30 | $119.91 Million | $10.51 Million | 0.088x | +155.18% |
| 2022-09-30 | $108.39 Million | $-17.22 Million | -0.159x | -244.64% |
| 2021-09-30 | $140.09 Million | $15.39 Million | 0.110x | +2.76% |
| 2020-09-30 | $131.06 Million | $14.01 Million | 0.107x | +62.94% |
| 2019-09-30 | $122.52 Million | $8.04 Million | 0.066x | -79.07% |
| 2018-09-30 | $108.61 Million | $34.05 Million | 0.314x | +148.89% |
| 2017-09-30 | $111.56 Million | $14.05 Million | 0.126x | -46.52% |
| 2016-09-30 | $106.83 Million | $25.17 Million | 0.236x | +46.43% |
| 2015-09-30 | $93.37 Million | $15.02 Million | 0.161x | -12.64% |
| 2014-09-30 | $98.75 Million | $18.18 Million | 0.184x | -2.20% |
| 2013-09-30 | $93.82 Million | $17.66 Million | 0.188x | +10.66% |
| 2012-09-30 | $94.69 Million | $16.11 Million | 0.170x | +23.92% |
| 2011-09-30 | $145.34 Million | $19.95 Million | 0.137x | -3.70% |
| 2010-09-30 | $154.36 Million | $22.01 Million | 0.143x | -21.53% |
| 2009-09-30 | $172.37 Million | $31.32 Million | 0.182x | -35.29% |
| 2008-09-30 | $141.81 Million | $39.82 Million | 0.281x | -27.50% |
| 2007-09-30 | $130.92 Million | $50.71 Million | 0.387x | +59.43% |
| 2006-09-30 | $145.20 Million | $35.28 Million | 0.243x | +8.22% |
| 2005-09-30 | $115.58 Million | $25.95 Million | 0.225x | +8.85% |
| 2004-09-30 | $94.50 Million | $19.49 Million | 0.206x | -7.77% |
| 2003-09-30 | $86.11 Million | $19.26 Million | 0.224x | +9.36% |
| 2002-09-30 | $70.00 Million | $14.31 Million | 0.204x | +45.82% |
| 2001-09-30 | $55.70 Million | $7.81 Million | 0.140x | -8.18% |
| 2000-09-30 | $48.30 Million | $7.38 Million | 0.153x | +3.09% |
| 1999-09-30 | $29.70 Million | $4.40 Million | 0.148x | +60.14% |
| 1998-09-30 | $22.70 Million | $2.10 Million | 0.093x | -- |
About SurModics Inc
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision o… Read more